mail2

NMOtion™ Blog

Discussing NMO Research and Advocacy

FDA Approves Genentech’s Enspryng for Neuromyelitis Optica Spectrum Disorder

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng (satralizumab-mwge) as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, lifelong and debilitating autoimmune disorder of the central nervous system, often misdiagnosed as multiple sclerosis, that primarily damages the optic nerve(s) and spinal cord, causing blindness, muscle weakness and paralysis.

Read the Press Release.

Visit ENSPRYNG.com

Launch Dashboard

Dashboard

Fast Facts about NMOSD